Display options
Cite
Fruytier AC, Le Duff CS, Po C, et al. The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Front Pharmacol. 2016;7:506doi: 10.3389/fphar.2016.00506.
Fruytier, A. C., Le Duff, C. S., Po, C., Magat, J., Bouzin, C., Neveu, M. A., Feron, O., Jordan, B. F., & Gallez, B. (2016). The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Frontiers in pharmacology, 7506. https://doi.org/10.3389/fphar.2016.00506
Fruytier, Anne-Catherine, et al. "The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma." Frontiers in pharmacology vol. 7 (2016): 506. doi: https://doi.org/10.3389/fphar.2016.00506
Fruytier AC, Le Duff CS, Po C, Magat J, Bouzin C, Neveu MA, Feron O, Jordan BF, Gallez B. The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Front Pharmacol. 2016 Dec 23;7:506. doi: 10.3389/fphar.2016.00506. eCollection 2016. PMID: 28066252; PMCID: PMC5179558.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Dec 23;7:506. doi: 10.3389/fphar.2016.00506. eCollection 2016.

The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma.

Frontiers in pharmacology

Anne-Catherine Fruytier, Cecile S Le Duff, Chrystelle Po, Julie Magat, Caroline Bouzin, Marie-Aline Neveu, Olivier Feron, Benedicte F Jordan, Bernard Gallez

Affiliations

  1. Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium.
  2. Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain Louvain-la-Neuve, Belgium.
  3. Institut de Recherche Expérimentale et Clinique, Pole of Pharmacology, Angiogenesis and Cancer Research Laboratory, Université Catholique de Louvain Brussels, Belgium.

PMID: 28066252 PMCID: PMC5179558 DOI: 10.3389/fphar.2016.00506

Abstract

In recent clinical studies, vascular disrupting agents (VDAs) are mainly used in combination with chemotherapy. However, an often overlooked concern in treatment combination is the VDA-induced impairment of chemotherapy distribution in the tumor. The work presented here investigated the impact of blood flow shutdown induced by Combretastatin A4 (CA4) on gemcitabine uptake into mouse hepatocarcinoma. At 2 h after CA4 treatment, using DCE-MRI, a significant decrease in the perfusion-relevant parameters K

Keywords: 19F NMR; DCE-MRI; drug delivery; tumor perfusion; vascular disrupting agent

References

  1. Cancer Res. 1992 Feb 1;52(3):533-9 - PubMed
  2. Front Oncol. 2013 Oct 01;3:259 - PubMed
  3. Clin Cancer Res. 2001 Oct;7(10):3263-8 - PubMed
  4. Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77 - PubMed
  5. Invest Radiol. 1989 Mar;24(3):224-7 - PubMed
  6. Br J Cancer. 2007 Jan 29;96(2):189-95 - PubMed
  7. Cancer Res. 1966 Jan;26(1):143-8 - PubMed
  8. Nat Med. 1995 Jan;1(1):27-31 - PubMed
  9. J Magn Reson Imaging. 1999 Sep;10(3):223-32 - PubMed
  10. Acta Oncol. 2010 Oct;49(7):906-13 - PubMed
  11. Clin Cancer Res. 2002 Jun;8(6):1974-83 - PubMed
  12. Adv Drug Deliv Rev. 2012 Dec 1;64(Suppl):353-365 - PubMed
  13. Br J Cancer. 1999 Dec;81(8):1318-27 - PubMed
  14. Neoplasia. 2005 Oct;7(10 ):957-66 - PubMed
  15. Cancer Res. 2005 Jul 1;65(13):5785-91 - PubMed
  16. Solid State Nucl Magn Reson. 2002 Dec;22(4):458-483 - PubMed
  17. Cancer Treat Rev. 2011 Feb;37(1):63-74 - PubMed
  18. NMR Biomed. 2007 Apr;20(2):128-40 - PubMed
  19. NMR Biomed. 2014 Nov;27(11):1403-12 - PubMed
  20. Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53 - PubMed
  21. Nat Rev Cancer. 2005 Jun;5(6):423-35 - PubMed
  22. Ann Oncol. 2006 May;17 Suppl 5:v7-12 - PubMed
  23. Clin Cancer Res. 1996 Feb;2(2):359-67 - PubMed
  24. Cancer Chemother Pharmacol. 1997;39(6):541-6 - PubMed
  25. Magn Reson Med. 2014 Feb;71(2):544-50 - PubMed
  26. Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S164-82 - PubMed
  27. Clin Cancer Res. 2004 Jan 15;10 (2):415-27 - PubMed
  28. Science. 2009 Jun 12;324(5933):1457-61 - PubMed
  29. NMR Biomed. 2002 Apr;15(2):89-98 - PubMed
  30. Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52 - PubMed
  31. J Clin Oncol. 2012 Mar 1;30(7):760-1; author reply 761-3 - PubMed
  32. Cancer Sci. 2003 Feb;94(2):200-4 - PubMed
  33. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6 - PubMed
  34. Cancer Res. 2001 Apr 1;61(7):3039-44 - PubMed

Publication Types